Insmed vs Jazz Pharmaceuticals
INSM and JAZZ side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How INSM and JAZZ compare
Insmed is the larger company, worth 1.7 times as much as Jazz Pharmaceuticals ($27.0B against $15.6B).
Insmed grew revenue faster over the last twelve months (240% versus 13.5% for Jazz Pharmaceuticals).
Jazz Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 4.4% compared with −39.9% at Insmed.
Insmed scores higher on the StockData Score (8 against 7 for Jazz Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | INSM | JAZZ |
|---|---|---|
| Size and price | ||
| Market cap | $27.0B | $15.6B |
| Share price | $122.88 | $239.77 |
| Change, 1 year | −35.7% | 69.2% |
| Change, 5 years | 325% | 93.2% |
| Beta (5Y) | 0.83 | 0.20 |
| Employees | 1,664 | 2,890 |
| StockData Score | ||
| Total score | 8 (better) | 7 |
| Valuation score | 0 | 0 |
| Growth score | 3 (better) | 2 |
| Performance score | 2 | 3 (better) |
| Health score | 3 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 78.1× |
| P/S | 17.7× | 3.3× (better) |
| P/B | 37.1× | 3.7× (better) |
| EV/EBITDA | – | 42.9× |
| P/FCF | – | 9.6× |
| FCF yield | −2.3% | 10.4% (better) |
| Fair value | $61.54 | $108.36 |
| Margin of safety | −99.7% (better) | −121% |
| Growth | ||
| Revenue growth (TTM) | 240% (better) | 13.5% |
| Revenue growth, 5Y average | 29.8% (better) | 12.5% |
| Profitability | ||
| Gross margin | 84.4% | – |
| Operating margin | −37.1% | 9.0% (better) |
| Net margin | −39.9% | 4.4% (better) |
| FCF margin | −41.3% | 34.4% (better) |
| Return on equity | −72.5% | 5.1% (better) |
| Return on invested capital | – | 4.5% |
| Financial health | ||
| Debt / equity | 0.76 (better) | 1.33 |
| Net debt / EBITDA | – | 6.37 |
| Interest coverage | −6.9× | – |
| Current ratio | 2.86 (better) | 1.82 |
| Altman Z-score | 7.51 (better) | 1.96 |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 102% | 99.2% |
| Held by insiders | 0.89% | 3.4% |
| Insider net buying, 12 months | −$133M | −$67.1M (better) |
| Superinvestors holding | 1 | 1 |
| Short interest, % of float | 6.5% | 9.3% |
Go deeper
- INSM stock overview
- INSM income statement
- INSM valuation and score
- JAZZ stock overview
- JAZZ income statement
- JAZZ valuation and score
Other comparisons
- ALNY vs INSM
- ALNY vs JAZZ
- BBIO vs INSM
- BMRN vs JAZZ
- INSM vs KNSA
- INSM vs MDGL
- INSM vs RPRX
- INSM vs UTHR
- JAZZ vs ONC
For information only, not investment advice. Check the source filings before relying on any figure.